377 related articles for article (PubMed ID: 20424113)
21. Disulfiram/copper markedly induced myeloma cell apoptosis through activation of JNK and intrinsic and extrinsic apoptosis pathways.
Xu Y; Zhou Q; Feng X; Dai Y; Jiang Y; Jiang W; Liu X; Xing X; Wang Y; Ni Y; Zheng C
Biomed Pharmacother; 2020 Jun; 126():110048. PubMed ID: 32145587
[TBL] [Abstract][Full Text] [Related]
22. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Stemke-Hale K; Gonzalez-Angulo AM; Lluch A; Neve RM; Kuo WL; Davies M; Carey M; Hu Z; Guan Y; Sahin A; Symmans WF; Pusztai L; Nolden LK; Horlings H; Berns K; Hung MC; van de Vijver MJ; Valero V; Gray JW; Bernards R; Mills GB; Hennessy BT
Cancer Res; 2008 Aug; 68(15):6084-91. PubMed ID: 18676830
[TBL] [Abstract][Full Text] [Related]
23. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
Liu S; Tang Y; Yan M; Jiang W
Invest New Drugs; 2018 Oct; 36(5):763-772. PubMed ID: 29504069
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Bonelli MA; Cavazzoni A; Saccani F; Alfieri RR; Quaini F; La Monica S; Galetti M; Cretella D; Caffarra C; Madeddu D; Frati C; Lagrasta CA; Falco A; Rossetti P; Fumarola C; Tiseo M; Petronini PG; Ardizzoni A
Mol Cancer Ther; 2015 Aug; 14(8):1916-27. PubMed ID: 26013318
[TBL] [Abstract][Full Text] [Related]
25. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.
Tanaka H; Yoshida M; Tanimura H; Fujii T; Sakata K; Tachibana Y; Ohwada J; Ebiike H; Kuramoto S; Morita K; Yoshimura Y; Yamazaki T; Ishii N; Kondoh O; Aoki Y
Clin Cancer Res; 2011 May; 17(10):3272-81. PubMed ID: 21558396
[TBL] [Abstract][Full Text] [Related]
26. PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation.
Jang K; Kim M; Seo HS; Shin I
Oncol Rep; 2010 Sep; 24(3):787-93. PubMed ID: 20664988
[TBL] [Abstract][Full Text] [Related]
27. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
28. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.
Liu D; Hou P; Liu Z; Wu G; Xing M
Cancer Res; 2009 Sep; 69(18):7311-9. PubMed ID: 19706758
[TBL] [Abstract][Full Text] [Related]
29. AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
Dunn S; Eberlein C; Yu J; Gris-Oliver A; Ong SH; Yelland U; Cureton N; Staniszewska A; McEwen R; Fox M; Pilling J; Hopcroft P; Coker EA; Jaaks P; Garnett MJ; Isherwood B; Serra V; Davies BR; Barry ST; Lynch JT; Yusa K
Oncogene; 2022 Nov; 41(46):5046-5060. PubMed ID: 36241868
[TBL] [Abstract][Full Text] [Related]
30. PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN.
Chong X; Chen J; Zheng N; Zhou Z; Hai Y; Chen S; Zhang Y; Yu Q; Yu S; Chen Z; Bao W; Quan M; Chen ZS; Zhan Y; Gao Y
Mol Cancer; 2022 May; 21(1):118. PubMed ID: 35619132
[TBL] [Abstract][Full Text] [Related]
31. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
[TBL] [Abstract][Full Text] [Related]
32. Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy.
Yu K; Toral-Barza L; Shi C; Zhang WG; Zask A
Cancer Biol Ther; 2008 Feb; 7(2):307-15. PubMed ID: 18059185
[TBL] [Abstract][Full Text] [Related]
33. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
[TBL] [Abstract][Full Text] [Related]
34. In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
Kong D; Yamori T; Yamazaki K; Dan S
Invest New Drugs; 2014 Dec; 32(6):1134-43. PubMed ID: 25152245
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway.
Miao Y; Zheng W; Li N; Su Z; Zhao L; Zhou H; Jia L
Sci Rep; 2017 Feb; 7():41942. PubMed ID: 28165066
[TBL] [Abstract][Full Text] [Related]
36. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
Young CD; Zimmerman LJ; Hoshino D; Formisano L; Hanker AB; Gatza ML; Morrison MM; Moore PD; Whitwell CA; Dave B; Stricker T; Bhola NE; Silva GO; Patel P; Brantley-Sieders DM; Levin M; Horiates M; Palma NA; Wang K; Stephens PJ; Perou CM; Weaver AM; O'Shaughnessy JA; Chang JC; Park BH; Liebler DC; Cook RS; Arteaga CL
Mol Cell Proteomics; 2015 Jul; 14(7):1959-76. PubMed ID: 25953087
[TBL] [Abstract][Full Text] [Related]
37. Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.
Chung WP; Huang WL; Liao WA; Huang WL; Liu YY; Su WC
Cancer Med; 2021 Apr; 10(7):2370-2379. PubMed ID: 33665980
[TBL] [Abstract][Full Text] [Related]
38. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
Vora SR; Juric D; Kim N; Mino-Kenudson M; Huynh T; Costa C; Lockerman EL; Pollack SF; Liu M; Li X; Lehar J; Wiesmann M; Wartmann M; Chen Y; Cao ZA; Pinzon-Ortiz M; Kim S; Schlegel R; Huang A; Engelman JA
Cancer Cell; 2014 Jul; 26(1):136-49. PubMed ID: 25002028
[TBL] [Abstract][Full Text] [Related]
39. Antitumor effects of disulfiram/copper complex in the poorly-differentiated nasopharyngeal carcinoma cells via activating ClC-3 chloride channel.
Xu X; Xu J; Zhao C; Hou X; Li M; Wang L; Chen L; Chen Y; Zhu L; Yang H
Biomed Pharmacother; 2019 Dec; 120():109529. PubMed ID: 31606620
[TBL] [Abstract][Full Text] [Related]
40. Suppressing autophagy enhances disulfiram/copper-induced apoptosis in non-small cell lung cancer.
Wu X; Xue X; Wang L; Wang W; Han J; Sun X; Zhang H; Liu Y; Che X; Yang J; Wu C
Eur J Pharmacol; 2018 May; 827():1-12. PubMed ID: 29547841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
